Boston Scientific Secures $11B in Credit Facilities for Penumbra Acquisition

Boston Scientific Corporation (NYSE: BSX) has secured $11 billion in new credit facilities to support its pending acquisition of Penumbra, Inc., according to an 8-K filing with the SEC on February 26, 2026. The comprehensive financing package replaces the company's existing credit arrangements and provides substantial flexibility for the transformative deal announced in January.

The Deal

The financing structure consists of three distinct credit agreements totaling $11 billion, all arranged through Wells Fargo Bank as administrative agent. The package includes a $3 billion five-year revolving credit facility maturing in February 2031, a $2 billion 364-day revolving credit facility, and a $6 billion term loan credit agreement split into two tranches.

The term loan facility is specifically designed for the Penumbra acquisition, with $1 billion available in Tranche A and $5 billion in Tranche B. Both tranches can only be drawn on the closing date of the acquisition and mature 364 days later. The Tranche B loan includes a unique feature requiring mandatory prepayment from any subsequent equity issuance or debt incurrence, effectively positioning it as bridge financing.

All facilities will bear interest based on Term SOFR plus applicable margins determined by Boston Scientific's credit rating. The company will also pay facility fees on the revolving credit commitments and ticking fees on undrawn portions beginning 120 days after the agreements' effective date.

Strategic Rationale

The substantial credit package reflects Boston Scientific's commitment to the Penumbra acquisition while maintaining financial flexibility. The $3 billion five-year revolver provides long-term working capital support with potential one-year extensions, replacing the company's previous 2021 revolving credit agreement.

The financing structure demonstrates prudent capital management through its layered approach. The 364-day facilities offer short-term acquisition financing with built-in incentives for refinancing, particularly the Tranche B term loan's mandatory prepayment provisions. This suggests Boston Scientific may pursue permanent financing through capital markets once the acquisition closes.

The credit agreements include covenant flexibility tailored for large acquisitions. The maximum leverage ratio of 3.75x can temporarily increase to 4.75x for four quarters following a qualified acquisition exceeding $1 billion, then gradually step down over the subsequent year. This accommodation specifically anticipates the Penumbra transaction's impact on the company's leverage metrics.

Notably, the agreements permit exclusions from consolidated EBITDA calculations including non-cash charges and up to $1.16 billion in cash litigation payments since December 31, 2025, providing additional covenant cushion during the integration period.

What to Watch

The timing mechanics of these facilities create several key milestones for investors to monitor. The 364-day facilities mature either 364 days from when loans become available or from the Penumbra acquisition closing, whichever occurs first. This structure incentivizes prompt deal completion while providing certainty on the financing timeline.

Ticking fees beginning 120 days after the effective date add carrying costs to undrawn commitments, creating economic pressure to either complete the acquisition or terminate unnecessary facilities. The Tranche B term loan's additional 0.10% duration fee payable 90 days post-closing further encourages rapid refinancing.

The automatic reduction provisions for Tranche B commitments before closing mean any pre-acquisition capital raising will directly reduce the bridge financing needs. This feature allows Boston Scientific to optimize its capital structure opportunistically while maintaining committed acquisition funding.

Regulatory considerations remain minimal from a financing perspective, as the credit agreements are already effective. However, the acquisition itself still requires customary closing conditions, and any delays would impact the financing timeline and associated carrying costs.

The replacement of Boston Scientific's 2021 credit facility with the new $3 billion revolver modernizes the company's core credit infrastructure while aligning it with the expanded scale post-acquisition. The five-year term with extension options provides stability through the integration period and beyond.

For Boston Scientific shareholders, this comprehensive financing package removes execution risk around acquisition funding while maintaining flexibility for permanent financing optimization. The structured approach balances committed funding certainty with economic incentives for efficient capital management, positioning the company to execute one of the medical device industry's most significant recent transactions.

*Source: Boston Scientific Corporation Form 8-K filed February 26, 2026*

StockCliff Research